Carvedilol is recommended in patients with compensated advanced chronic liver disease(cACLD)and clinically significant portal hypertension(CSPH)to prevent hepatic decompensation(1).However,as hepatic venous pressure g...Carvedilol is recommended in patients with compensated advanced chronic liver disease(cACLD)and clinically significant portal hypertension(CSPH)to prevent hepatic decompensation(1).However,as hepatic venous pressure gradient(HVPG)measurement,the minimally invasive gold standard for the diagnosis of CSPH,is not broadly available,decision rules based on non-invasive tests(NITs)are needed(2).展开更多
At the beginning of the 21st century,in a global attempt to guide and organize the treatment of hepatocellular carcinoma(HCC),which had reached 7th place as the most frequent cancer due to the historical coincidence o...At the beginning of the 21st century,in a global attempt to guide and organize the treatment of hepatocellular carcinoma(HCC),which had reached 7th place as the most frequent cancer due to the historical coincidence of three confluent pandemics worldwide(alcoholism,obesity and viral hepatitis),several HCC classification proposals arose,among them,the one elaborated by Llovet et al.,members of the Liver Unit of Barcelona Clinic Hospital,who published the first version of the Barcelona Clinic Liver Cancer(BCLC)in 1999.展开更多
Hepatocellular carcinoma(HCC)is the third leading cause of cancer-related deaths worldwide(1).It often arises from the backgrounds of damaged liver due to viral hepatitis,alcoholic,or non-alcoholic liver disease.Altho...Hepatocellular carcinoma(HCC)is the third leading cause of cancer-related deaths worldwide(1).It often arises from the backgrounds of damaged liver due to viral hepatitis,alcoholic,or non-alcoholic liver disease.Although the proportion of patients with HCC of non-hepatitis B and C origins has increased in recent years,hepatitis B and C viruses still cause more than half of all carcinogenesis in patients with HCC(2).Patients with HCC often develop portal hypertension(PHT)from cirrhosis due to the deterioration of the background liver,which proves to be the greatest obstacle to various types of treatments for HCC.展开更多
基金supported by the Clinical Research Group MOTION,Medical University of Vienna,Vienna,Austria-a project funded by the Clinical Research Groups Programme of the Ludwig Boltzmann Gesellschaft(grant No.LBG_KFG_22_32)with funds from the Fonds ZukunftÖsterreich(to G.S.,M.J.,and M.M.).
文摘Carvedilol is recommended in patients with compensated advanced chronic liver disease(cACLD)and clinically significant portal hypertension(CSPH)to prevent hepatic decompensation(1).However,as hepatic venous pressure gradient(HVPG)measurement,the minimally invasive gold standard for the diagnosis of CSPH,is not broadly available,decision rules based on non-invasive tests(NITs)are needed(2).
文摘At the beginning of the 21st century,in a global attempt to guide and organize the treatment of hepatocellular carcinoma(HCC),which had reached 7th place as the most frequent cancer due to the historical coincidence of three confluent pandemics worldwide(alcoholism,obesity and viral hepatitis),several HCC classification proposals arose,among them,the one elaborated by Llovet et al.,members of the Liver Unit of Barcelona Clinic Hospital,who published the first version of the Barcelona Clinic Liver Cancer(BCLC)in 1999.
文摘Hepatocellular carcinoma(HCC)is the third leading cause of cancer-related deaths worldwide(1).It often arises from the backgrounds of damaged liver due to viral hepatitis,alcoholic,or non-alcoholic liver disease.Although the proportion of patients with HCC of non-hepatitis B and C origins has increased in recent years,hepatitis B and C viruses still cause more than half of all carcinogenesis in patients with HCC(2).Patients with HCC often develop portal hypertension(PHT)from cirrhosis due to the deterioration of the background liver,which proves to be the greatest obstacle to various types of treatments for HCC.
